139
Participants
Start Date
August 2, 2022
Primary Completion Date
June 25, 2024
Study Completion Date
July 15, 2024
Placebo capsules
Treatment was blind for the whole duration of the study.
SOM3355 200 mg capsules
Treatment was blind for the whole duration of the study.
SOM3355 300 mg capsules
Treatment was blind for the whole duration of the study.
Centre Hospitalier Universitaire Angers, Angers
CHU Hôpital Henri Mondor (APHP), Créteil
Hôpital Roger Salengro - CHU Lille, Lille
Hopital de Hautepierre, Strasbourg
Hôpital Purpan - CHU Toulouse, Toulouse
Charité - Universitätsmedizin Berlin, Berlin
George Huntington Institut, Münster
Kbo-Isar-Amper-Klinikum Taufkirchen, Taufkirchen
Hospital of University of Ulm, Ulm
IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna
Azienda Ospedaliera Universitaria Federico II, Napoli
IRCCS Casa Sollievo della Sofferenza, Roma
Sant'Andrea University Hospital, Roma
Krakowska Akademia Neurologii Sp. z o.o., Krakow
Indywidualna Praktyka Lekarska Daniel Zielonka, Poznan
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Universitario de Cruces, Bilbao
Hospital Universitario de Burgos, Burgos
Hospital Ramón y Cajal, Madrid
Universitaetsspital Bern - Inselspital, Bern
Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital, Cambridge
NIHR Wellcome Trust Manchester Clinical Research Facility, Manchester
Oxford University Hospitals NHS Foundation Trust, Oxford
SOM Innovation Biotech SA
INDUSTRY